TY  - GEN
AU  - Leiter, L A
AU  - Tinahones, F J
AU  - Karalis, D G
AU  - Bujas-Bobanovic, M
AU  - Letierce, A
AU  - Mandel, J
AU  - Samuel, R
AU  - Jones, P H
PY  - 2018
DO  - 10.1111/dme.13817
UR  - http://hdl.handle.net/20.500.12105/17632
AB  - To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. Safety data from 14 trials (8-104-week durations) were analysed by treatment (alirocumab or...
LA  - eng
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Diabetes Complications
KW  - Diabetes Mellitus
TI  - Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
TY  - research article
ER  -